Kalytera Therapeutics Provides Update for Lead Program in Prevention and Treatment of GVHD
SAN FRANCISCO and TEL AVIV, Israel, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today provided an update on its lead product development program …